05.02.2025 • News

ChiralVision and Ecovyst Partner on Industrial Biocatalysis

Ecovyst, a provider of advanced materials, specialty catalysts, sulfuric acid and regeneration services, and ChiralVision, a developer of biocatalysis-based technologies have signed a Memorandum of Understanding (MOU) for a partnership in the field of enzyme immobilization.

By combining their strengths, the two companies aim to develop technologies that improve the efficiency and sustainability of enzyme-based processes in industrial biocatalysis.

"Biocatalysis, and in particular enzyme immobilization, is the key to economical and sustainable commercial production. Through the collaboration with Ecovyst, one of the largest and most innovative advanced materials and specialty catalysts manufacturers in the world, we can support larger and more complex development projects and let our commercial scale production of immobilized enzymes grow further," said Rob Schoevaart, managing director of ChiralVision.

Paul Whittleston, president of Advanced Materials & Catalysts at Ecovyst, added: "This partnership perfectly aligns with Ecovyst's commitment to drive innovation through material science expertise. Our deep knowledge of silica technology and ability to tailor its properties for specific applications have played a crucial role in optimizing the immobilization process, enabling improved enzyme stability and performance. Together with ChiralVision, we are shaping solutions that meet the growing demand for greener, more cost-effective industrial processes."

© Shutterstock / bluebay
© Shutterstock / bluebay

Company

Ecovyst Inc.



US

Company contact







Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read